Physician profile
Scott A Limstrom
NPI 1366421885
$2,202.27
in general payments reported to CMS, 2019-2025
12 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2021: $347 · 2022: $604 · 2023: $549 · 2024: $439 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $763.21 | 2021-2025 | Eylea, Eylea Hd |
| Alcon Vision LLC | $630.77 | 2019-2024 | Constellation |
| Genentech USA, INC. | $240.47 | 2022-2025 | Vabysmo |
| Genentech, INC. | $132.60 | 2022 | |
| Abbvie INC. | $122.20 | 2022-2025 | |
| Alimera Sciences, INC. | $84.37 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $79.26 | 2023 | Syfovre |
| Astellas Pharma US INC | $49.37 | 2024 | Izervay |
| Eyepoint US, INC. | $45.40 | 2021-2022 | |
| Coherus Oncology, INC. | $20.07 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.66 | 2019 | |
| Allergan, INC. | $15.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Limstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.